PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1880596
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1880596
Aminoglycosides Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Factors of aminoglycosides Market
The global aminoglycosides market continues to grow steadily, driven by rising bacterial infections, advancements in antibiotic technologies, and increasing demand for effective treatments for complicated respiratory and urinary tract infections. According to the latest industry report, the market size was USD 1.87 billion in 2024, projected to rise to USD 1.92 billion in 2025, and expected to reach USD 2.35 billion by 2032, expanding at a CAGR of 2.95%. In 2024, North America led the market with a 41.17% share, supported by robust healthcare systems, strong antibiotic stewardship programs, and higher adoption of aminoglycosides for critical care management.
Aminoglycosides-such as gentamicin, tobramycin, amikacin, streptomycin, and neomycin-remain essential bactericidal antibiotics used in treating severe infections. Their unique mechanism of binding to the bacterial 30S ribosomal subunit disrupts protein synthesis, making them especially effective against gram-negative pathogens. Their synergy with B-lactam antibiotics further strengthens their use in intensive care units. Technological innovations, including inhaled formulations and semi-synthetic derivatives, are enhancing safety, delivery, and therapeutic efficiency. Research activities, such as Stanford University's 2022 study aiming to develop hearing-loss-safe aminoglycosides, continue to elevate market potential.
Market Dynamics
Market Drivers
A key driver contributing to market uptake is the rising global prevalence of urinary tract infections (UTIs). Factors such as population aging, increasing diabetes incidence, lifestyle changes, and hospital-acquired infections have accelerated antibiotic demand. Responding to these trends, companies are expanding portfolios and introducing new solutions. In 2024, Cipla received approval from CDSCO to market Plazomicin, a next-generation aminoglycoside for complicated UTIs in India, reflecting growing commercial investments.
Market Restraints
The increasing global threat of antimicrobial resistance (AMR) poses a substantial barrier to market growth. Resistance in pathogens such as E. coli, K. pneumoniae, and P. aeruginosa is rising sharply. CDC reported in 2023 that aminoglycoside-resistant gram-negative infections are spreading across U.S. hospitals, while ECDC noted in 2024 that resistance in K. pneumoniae bloodstream infections exceeded 25% in parts of Europe. These trends challenge the long-term efficacy and adoption of aminoglycosides.
Market Opportunities
Despite resistance concerns, a promising opportunity lies in peptide-linked aminoglycoside conjugates, which restore the effectiveness of existing drugs against MDR organisms. A 2025 Frontiers in Microbiology study revealed strong synergistic action between peptide-neomycin conjugates and polymyxin B, highlighting the potential of modified aminoglycosides to overcome enzymatic drug inactivation.
Market Challenges
A major challenge is the risk of ototoxicity and nephrotoxicity, especially for individuals with rare mitochondrial mutations. Even when dosed within therapeutic ranges, aminoglycosides can cause irreversible hearing loss. The U.K. government's 2021 warning about narrow therapeutic windows reflects ongoing safety concerns that may limit broader clinical adoption.
Segmentation Highlights
By Generation
The third-generation aminoglycosides segment dominated in 2024, supported by increasing infection rates and high efficacy. Strategic licensing agreements-such as Sihuan Pharmaceutical's 2022 collaboration for Benapenem and Plazomicin-reinforce segment leadership.
By Application
In 2024, respiratory tract infections led the market due to rising MDR-Pseudomonas cases and growing cystic fibrosis prevalence. The CDC reported 35,000 people living with CF in the U.S., driving demand for advanced inhaled aminoglycosides.
By Route of Administration
The topical segment dominated in 2024 owing to localized action and lower systemic risk. In 2024, Appili Therapeutics advanced ATI-1801, a topical paromomycin formulation for cutaneous leishmaniasis.
By Distribution Channel
Retail pharmacies led the global market in 2024, driven by improved accessibility and high trust levels among patients. Pharmaprix's 2024 clinic expansion reflects growth in retail-based antibiotic dispensing.
Regional Outlook
North America remained the largest regional market in 2024 with revenues of USD 0.77 billion, backed by established healthcare systems and strong antibiotic R&D. Europe is forecast to reach USD 0.49 billion in 2025, supported by antimicrobial stewardship and regulatory oversight. Asia Pacific is projected to attain USD 0.32 billion in 2025, driven by rising infectious disease burdens and expanding pharmaceutical infrastructure. Latin America is expected to reach USD 0.20 billion in 2025, with moderate growth across emerging markets.
Conclusion
With the market projected to grow from USD 1.87 billion in 2024 to USD 2.35 billion by 2032, the aminoglycosides sector continues to evolve through product innovation, combination therapy expansion, and advanced antibiotic development. Despite AMR and toxicity challenges, sustained R&D and improved drug formulations are expected to support stable long-term market growth.
Segmentation By Generation
- First Generation
- Second Generation
- Third Generation
- Others
By Application
- Urinary Tract Infections
- Respiratory Tract Infection
- Skin Infections
- Ophthalmic Infections
- Others
By Route of Administration
- Oral
- Parenteral
- Topical
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Geography
- North America (By Generation, Application, Route of Administration, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Generation, Application, Route of Administration, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Overview of Key Diseases, By Key Countries/ Region, 2024
- 4.2. Regulatory Scenario by Key Countries/ Region, 2024
- 4.3. Pipeline Analysis, By Key Players
- 4.4. Overview of Antimicrobial Treatment Guidelines
- 4.5. Overview of the Antibiotic resistant "Priority Pathogens" Published by WHO
- 4.6. Key Industry Developments- Mergers, Acquisitions, Partnerships, etc.
5. Global Aminoglycosides Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast - By Generation
- 5.1.1. First Generation
- 5.1.2. Second Generation
- 5.1.3. Third Generation
- 5.1.4. Others
- 5.2. Market Analysis, Insights and Forecast - By Application
- 5.2.1. Urinary Tract Infections
- 5.2.2. Respiratory Tract Infection
- 5.2.3. Skin Infections
- 5.2.4. Opthalmic Infections
- 5.2.5. Others
- 5.3. Market Analysis, Insights and Forecast - By Route of Administration
- 5.3.1. Oral
- 5.3.2. Parenteral
- 5.3.3. Topical
- 5.3.4. Others
- 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.4.1. Hospital Pharmacy
- 5.4.2. Retail Pharmacy
- 5.4.3. Online Pharmacy
- 5.5. Market Analysis, Insights and Forecast - Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Aminoglycosides Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast - By Generation
- 6.1.1. First Generation
- 6.1.2. Second Generation
- 6.1.3. Third Generation
- 6.1.4. Others
- 6.2. Market Analysis, Insights and Forecast - By Application
- 6.2.1. Urinary Tract Infections
- 6.2.2. Respiratory Tract Infection
- 6.2.3. Skin Infections
- 6.2.4. Opthalmic Infections
- 6.2.5. Others
- 6.3. Market Analysis, Insights and Forecast - By Route of Administration
- 6.3.1. Oral
- 6.3.2. Parenteral
- 6.3.3. Topical
- 6.3.4. Others
- 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.4.1. Hospital Pharmacy
- 6.4.2. Retail Pharmacy
- 6.4.3. Online Pharmacy
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Aminoglycosides Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast - By Generation
- 7.1.1. First Generation
- 7.1.2. Second Generation
- 7.1.3. Third Generation
- 7.1.4. Others
- 7.2. Market Analysis, Insights and Forecast - By Application
- 7.2.1. Urinary Tract Infections
- 7.2.2. Respiratory Tract Infection
- 7.2.3. Skin Infections
- 7.2.4. Opthalmic Infections
- 7.2.5. Others
- 7.3. Market Analysis, Insights and Forecast - By Route of Administration
- 7.3.1. Oral
- 7.3.2. Parenteral
- 7.3.3. Topical
- 7.3.4. Others
- 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.4.1. Hospital Pharmacy
- 7.4.2. Retail Pharmacy
- 7.4.3. Online Pharmacy
- 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.5.1. Germany
- 7.5.2. U.K.
- 7.5.3. France
- 7.5.4. Italy
- 7.5.5. Spain
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
8. Asia Pacific Aminoglycosides Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast - By Generation
- 8.1.1. First Generation
- 8.1.2. Second Generation
- 8.1.3. Third Generation
- 8.1.4. Others
- 8.2. Market Analysis, Insights and Forecast - By Application
- 8.2.1. Urinary Tract Infections
- 8.2.2. Respiratory Tract Infection
- 8.2.3. Skin Infections
- 8.2.4. Opthalmic Infections
- 8.2.5. Others
- 8.3. Market Analysis, Insights and Forecast - By Route of Administration
- 8.3.1. Oral
- 8.3.2. Parenteral
- 8.3.3. Topical
- 8.3.4. Others
- 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.4.1. Hospital Pharmacy
- 8.4.2. Retail Pharmacy
- 8.4.3. Online Pharmacy
- 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.5.1. China
- 8.5.2. Japan
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America Aminoglycosides Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast - By Generation
- 9.1.1. First Generation
- 9.1.2. Second Generation
- 9.1.3. Third Generation
- 9.1.4. Others
- 9.2. Market Analysis, Insights and Forecast - By Application
- 9.2.1. Urinary Tract Infections
- 9.2.2. Respiratory Tract Infection
- 9.2.3. Skin Infections
- 9.2.4. Opthalmic Infections
- 9.2.5. Others
- 9.3. Market Analysis, Insights and Forecast - By Route of Administration
- 9.3.1. Oral
- 9.3.2. Parenteral
- 9.3.3. Topical
- 9.3.4. Others
- 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.4.1. Hospital Pharmacy
- 9.4.2. Retail Pharmacy
- 9.4.3. Online Pharmacy
- 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
10. Middle East & Africa Aminoglycosides Market Analysis, Insights and Forecast, 2019-2032
- 10.1. Market Analysis, Insights and Forecast - By Generation
- 10.1.1. First Generation
- 10.1.2. Second Generation
- 10.1.3. Third Generation
- 10.1.4. Others
- 10.2. Market Analysis, Insights and Forecast - By Application
- 10.2.1. Urinary Tract Infections
- 10.2.2. Respiratory Tract Infection
- 10.2.3. Skin Infections
- 10.2.4. Opthalmic Infections
- 10.2.5. Others
- 10.3. Market Analysis, Insights and Forecast - By Route of Administration
- 10.3.1. Oral
- 10.3.2. Parenteral
- 10.3.3. Topical
- 10.3.4. Others
- 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.4.1. Hospital Pharmacy
- 10.4.2. Retail Pharmacy
- 10.4.3. Online Pharmacy
- 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2024)
- 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability)
- 11.2.1. Amneal Pharmaceuticals, Inc.
- 11.2.2. Hikma Pharmaceuticals PLC
- 11.2.3. Insmed Incorporated
- 11.2.4. Pfizer Inc.
- 11.2.5. Cipla
- 11.2.6. Nordic Group B.V.
- 11.2.7. Lupin
- 11.2.8. Sun Pharmaceutical Industries Ltd.
- 11.2.9. Dr. Reddy's Laboratories Ltd.
List of Tables
- Table 1: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2019-2032
- Table 2: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2019-2032
- Table 3: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 4: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 5: Global Aminoglycosides Market Revenue (USD billion) Forecast, by Region, 2019-2032
- Table 6: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2019-2032
- Table 7: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2019-2032
- Table 8: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 9: North America Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 10: North America Aminoglycosides Market Revenue (USD billion) Forecast, By Country, 2019-2032
- Table 11: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2019-2032
- Table 12: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2019-2032
- Table 13: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 14: Europe Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 15: Europe Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 16: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2019-2032
- Table 17: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2019-2032
- Table 18: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 19: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 20: Asia Pacific Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 21: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2019-2032
- Table 22: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2019-2032
- Table 23: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 24: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 25: Latin America Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
- Table 26: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Generation, 2019-2032
- Table 27: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Application, 2019-2032
- Table 28: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Route of Administration, 2019-2032
- Table 29: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, by Distribution Channel, 2019-2032
- Table 30: Middle East & Africa Aminoglycosides Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032
List of Figures
- Figure 1: Global Aminoglycosides Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032
- Figure 2: Global Aminoglycosides Market Value Share (%), by Generation, 2024 & 2032
- Figure 3: Global Aminoglycosides Market Value Share (%), by Application, 2024 & 2032
- Figure 4: Global Aminoglycosides Market Value Share (%), by Route of Administration, 2024 & 2032
- Figure 5: Global Aminoglycosides Market Value Share (%), by Distribution Channel, 2024 & 2032
- Figure 6: Global Aminoglycosides Market Value Share (%), by Region, 2024 & 2032
- Figure 7: North America Aminoglycosides Market Value (USD billion), by Generation, 2024 & 2032
- Figure 8: North America Aminoglycosides Market Value Share (%), by Generation, 2024
- Figure 9: North America Aminoglycosides Market Value (USD billion), by Application, 2024 & 2032
- Figure 10: North America Aminoglycosides Market Value Share (%), by Application, 2024
- Figure 11: North America Aminoglycosides Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 12: North America Aminoglycosides Market Value Share (%), by Route of Administration, 2024
- Figure 13: North America Aminoglycosides Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 14: North America Aminoglycosides Market Value Share (%), by Distribution Channel, 2024
- Figure 15: North America Aminoglycosides Market Value (USD billion), By Country, 2024 & 2032
- Figure 16: North America Aminoglycosides Market Value Share (%), By Country, 2024
- Figure 17: Europe Aminoglycosides Market Value (USD billion), by Generation, 2024 & 2032
- Figure 18: Europe Aminoglycosides Market Value Share (%), by Generation, 2024
- Figure 19: Europe Aminoglycosides Market Value (USD billion), by Application, 2024 & 2032
- Figure 20: Europe Aminoglycosides Market Value Share (%), by Application, 2024
- Figure 21: Europe Aminoglycosides Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 22: Europe Aminoglycosides Market Value Share (%), by Route of Administration, 2024
- Figure 23: Europe Aminoglycosides Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 24: Europe Aminoglycosides Market Value Share (%), by Distribution Channel, 2024
- Figure 25: Europe Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 26: Europe Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2024
- Figure 27: Asia Pacific Aminoglycosides Market Value (USD billion), by Generation, 2024 & 2032
- Figure 28: Asia Pacific Aminoglycosides Market Value Share (%), by Generation, 2024
- Figure 29: Asia Pacific Aminoglycosides Market Value (USD billion), by Application, 2024 & 2032
- Figure 30: Asia Pacific Aminoglycosides Market Value Share (%), by Application, 2024
- Figure 31: Asia Pacific Aminoglycosides Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 32: Asia Pacific Aminoglycosides Market Value Share (%), by Route of Administration, 2024
- Figure 33: Asia Pacific Aminoglycosides Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 34: Asia Pacific Aminoglycosides Market Value Share (%), by Distribution Channel, 2024
- Figure 35: Asia Pacific Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 36: Asia Pacific Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2024
- Figure 37: Latin America Aminoglycosides Market Value (USD billion), by Generation, 2024 & 2032
- Figure 38: Latin America Aminoglycosides Market Value Share (%), by Generation, 2024
- Figure 39: Latin America Aminoglycosides Market Value (USD billion), by Application, 2024 & 2032
- Figure 40: Latin America Aminoglycosides Market Value Share (%), by Application, 2024
- Figure 41: Latin America Aminoglycosides Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 42: Latin America Aminoglycosides Market Value Share (%), by Route of Administration, 2024
- Figure 43: Latin America Aminoglycosides Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 44: Latin America Aminoglycosides Market Value Share (%), by Distribution Channel, 2024
- Figure 45: Latin America Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 46: Latin America Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2024
- Figure 47: Middle East & Africa Aminoglycosides Market Value (USD billion), by Generation, 2024 & 2032
- Figure 48: Middle East & Africa Aminoglycosides Market Value Share (%), by Generation, 2024
- Figure 49: Middle East & Africa Aminoglycosides Market Value (USD billion), by Application, 2024 & 2032
- Figure 50: Middle East & Africa Aminoglycosides Market Value Share (%), by Application, 2024
- Figure 51: Middle East & Africa Aminoglycosides Market Value (USD billion), by Route of Administration, 2024 & 2032
- Figure 52: Middle East & Africa Aminoglycosides Market Value Share (%), by Route of Administration, 2024
- Figure 53: Middle East & Africa Aminoglycosides Market Value (USD billion), by Distribution Channel, 2024 & 2032
- Figure 54: Middle East & Africa Aminoglycosides Market Value Share (%), by Distribution Channel, 2024
- Figure 55: Middle East & Africa Aminoglycosides Market Value (USD billion), By Country/ Sub-region, 2024 & 2032
- Figure 56: Middle East & Africa Aminoglycosides Market Value Share (%), By Country/ Sub-region, 2024
- Figure 57: Global Aminoglycosides Market Share (%), By Company, 2024
